Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MGAM | O43451 | 2/20 | 0.47 |
| ▸ | SI | P14410 | 2/20 | 0.47 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.47 |
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CCKAR | P32238 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750987 | 0.86 | KDM4E (0.57) | NPC1RAB9AALDH1A1MAPK1LMNA | |
| SCHEMBL19476165 | 0.81 | NPC1 (0.64) | NPC1RAB9AALDH1A1MAPK1LMNA | |
| SCHEMBL12368167 | 0.78 | MEN1 (0.60) | NPC1RAB9AALDH1A1MAPK1RXFP1 | |
| SCHEMBL5730899 | 0.77 | ALDH1A1 (0.57) | NPC1RAB9AALDH1A1RXFP1LMNA | |
| SCHEMBL14592325 | 0.77 | NPC1 (0.56) | NPC1RAB9AALDH1A1MAPK1LMNA | |
| SCHEMBL19476159 | 0.75 | NPC1 (0.70) | NPC1RAB9AALDH1A1RXFP1LMNA | |
| SCHEMBL10891943 | 0.75 | KMT2A (0.58) | ALDH1A1MAPK1RXFP1LMNASMN1; SMN2 | |
| SCHEMBL27336120 | 0.75 | RAB9A (0.73) | NPC1RAB9AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL19476098 | 0.74 | NPC1 (0.64) | NPC1RAB9AALDH1A1MAPK1LMNA | |
| SCHEMBL5739687 | 0.73 | TP53 (0.53) | NPC1RAB9AALDH1A1RXFP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633709-A1 | ANTI-DIABETIC AGENTS | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004096768-A1 | ANTI-DIABETIC AGENTS | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220229-A1 | insulin resistance; central nervous system disorders; vision defects; anticholesterol agents;antilipemic agents; antiischemic agents | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220229-A1 | insulin resistance; central nervous system disorders; vision defects; anticholesterol agents;antilipemic agents; antiischemic agents | IRS1, INSR, GPR119 | NPC1 15/4885RAB9A 1321/4885ALDH1A1 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.